Inventiva SACA
2,3400
18-февраля-25 10:39:18
15 мин. задержка
Акции
+0,0650
+2,86%
Сегодняшний диапазон
2,3200 - 2,3400
ISIN
FR0013233012
Источник
Cboe
- Котировки
- Графики
Новости
- Статистика
-
Inventiva to participate at the SVB Leerink CybeRx Series: Liver Disease Day
15 июн 2021 16:00:00 Источник Nasdaq GlobeNewswire
-
09 июн 2021 16:00:00 Источник Nasdaq GlobeNewswire
-
Inventiva to participate at the Jefferies Virtual Healthcare Conference
25 май 2021 16:00:00 Источник Nasdaq GlobeNewswire
-
12 май 2021 16:00:00 Источник Nasdaq GlobeNewswire
-
Inventiva to participate at the 7th Annual Truist Securities Life Sciences Summit
26 апр 2021 16:00:00 Источник Nasdaq GlobeNewswire
-
Appointment of Martine Zimmermann as Independent Director to Inventiva’s Board of Directors
19 апр 2021 16:00:00 Источник Nasdaq GlobeNewswire
-
Results of the votes of the Combined Shareholders’ Meeting of April 16, 2021
19 апр 2021 12:00:00 Источник Nasdaq GlobeNewswire
-
25 мар 2021 13:00:00 Источник Nasdaq GlobeNewswire
-
Statement of total voting rights and shares forming the company’s share capital on March 10th, 2021
25 мар 2021 10:43:35 Источник Nasdaq GlobeNewswire
-
15 мар 2021 17:00:00 Источник Nasdaq GlobeNewswire
-
04 мар 2021 16:00:00 Источник Nasdaq GlobeNewswire
-
25 фев 2021 16:00:00 Источник Nasdaq GlobeNewswire
-
Inventiva to participate at several investor conferences in March 2021
24 фев 2021 16:00:00 Источник Nasdaq GlobeNewswire
-
Inventiva’s 2020 Full-Year Financial Results Presentation
23 фев 2021 16:00:00 Источник Nasdaq GlobeNewswire
-
Full-Year 2020: Cash position and revenues
11 фев 2021 16:00:00 Источник Nasdaq GlobeNewswire
-
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
15 янв 2021 11:45:00 Источник Nasdaq GlobeNewswire
-
Inventiva annonce sa participation à la « 39th Annual J.P. Morgan Healthcare Conference »
06 янв 2021 16:00:00 Источник Nasdaq GlobeNewswire
-
Inventiva announces design of Phase III clinical trial with lanifibranor in NASH
05 янв 2021 16:00:00 Источник Nasdaq GlobeNewswire